Literature DB >> 22702330

Anaplastic medulloblastoma in a child with Duchenne muscular dystrophy.

Machiel van den Akker1, Paul Northcott, Michael D Taylor, William Halliday, Ute Bartels, Eric Bouffet.   

Abstract

A 9-year-old boy with known Duchenne type muscular dystrophy (DMD) presented with signs of increased intracranial pressure. Radiological investigations revealed a lesion in the midline of the posterior fossa. Subtotal resection was performed. Pathology findings were consistent with the diagnosis of anaplastic medulloblastoma. The postoperative lumbar CSF was positive for malignant cells. Postoperatively, the patient showed severe neurological deterioration and lost his capacity to walk. He was treated with craniospinal radiation followed by nonintensive chemotherapy. At 30 months postsurgery, he was still in complete remission but had not recovered his walking ability. This is the second report of a malignant brain tumor in a boy with DMD. The possible link between the 2 conditions is discussed, as are ethical considerations regarding the management of medulloblastoma in children with DMD.

Entities:  

Mesh:

Year:  2012        PMID: 22702330     DOI: 10.3171/2012.3.PEDS11152

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  3 in total

1.  Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients?

Authors:  Vijay Ramaswamy; Marc Remke; Jennifer Adamski; Ute Bartels; Uri Tabori; Xin Wang; Annie Huang; Cynthia Hawkins; Donald Mabbott; Normand Laperriere; Michael D Taylor; Eric Bouffet
Journal:  Neuro Oncol       Date:  2015-01-20       Impact factor: 12.300

Review 2.  The Duchenne muscular dystrophy gene and cancer.

Authors:  Leanne Jones; Michael Naidoo; Lee R Machado; Karen Anthony
Journal:  Cell Oncol (Dordr)       Date:  2020-11-14       Impact factor: 6.730

3.  Cancer-related genes in the transcription signature of facioscapulohumeral dystrophy myoblasts and myotubes.

Authors:  Petr Dmitriev; Ulykbek Kairov; Thomas Robert; Ana Barat; Vladimir Lazar; Gilles Carnac; Dalila Laoudj-Chenivesse; Yegor S Vassetzky
Journal:  J Cell Mol Med       Date:  2013-12-17       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.